FDA OTC Labeling Final Rule Based On "Unrealistic Assumptions" - CHPA
FDA's final rule on OTC labeling "appears to be based on unrealistic assumptions," Consumer Healthcare Products Association Senior VP and Director of Science & Technology William Soller, PhD, asserted at an FDA "feedback" meeting April 23. "A number of examples used by FDA" as samples of OTC labels "are unrealistic projections of actual labeling," Soller added.
More from Archive
More from Pink Sheet
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.